PLAU and cancer: To enhance their antitumorigenic effect, urokinase plasminogen activator (uPA) antibodies can be conjugated with liposomal nanobins to target the urokinase system, which is overexpressed in cancer cells but expressed at low levels in normal cells [26,37].